Dynavax Technologies Corporation (NASDAQ:DVAX) Given Average Rating of "Hold" by Brokerages

Key Points

• Dynavax Technologies Corporation has received an average rating of "Hold" from five research firms, with a price target averaging $24.33.
• Director Scott Dunseth Myers recently purchased 3,800 shares of the company, increasing his position by 12.18%.
• Dynavax Technologies reported a quarterly earnings per share of $0.14, exceeding expectations, with revenues of $95.44 million during the quarter.

Dynavax Technologies Corporation (NASDAQ:DVAX - Get Free Report) has earned an average rating of "Hold" from the five research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $24.3333.

Several equities analysts have commented on DVAX shares. JMP Securities reaffirmed a "market outperform" rating and issued a $32.00 price target on shares of Dynavax Technologies in a report on Friday, August 22nd. Weiss Ratings restated a "sell (d)" rating on shares of Dynavax Technologies in a research report on Saturday, September 27th. Finally, Wall Street Zen upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th.

Insider Buying and Selling at Dynavax Technologies

In related news, Director Scott Dunseth Myers purchased 3,800 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were bought at an average price of $10.82 per share, with a total value of $41,116.00. Following the purchase, the director directly owned 35,004 shares in the company, valued at $378,743.28. This trade represents a 12.18% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 2.98% of the stock is currently owned by company insiders.

Institutional Trading of Dynavax Technologies

Hedge funds have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale acquired a new stake in Dynavax Technologies during the 1st quarter worth $30,000. Caitong International Asset Management Co. Ltd grew its holdings in Dynavax Technologies by 5,485.7% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,304 shares during the period. GAMMA Investing LLC grew its holdings in Dynavax Technologies by 88.4% during the first quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 3,627 shares during the period. Osaic Holdings Inc. grew its holdings in Dynavax Technologies by 15.1% during the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 1,226 shares during the period. Finally, Moloney Securities Asset Management LLC bought a new position in Dynavax Technologies during the first quarter worth about $131,000. Institutional investors and hedge funds own 96.96% of the company's stock.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX remained flat at $10.10 during trading hours on Friday. The company had a trading volume of 1,240,581 shares, compared to its average volume of 2,052,417. Dynavax Technologies has a fifty-two week low of $9.20 and a fifty-two week high of $14.63. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. The stock has a market cap of $1.18 billion, a PE ratio of -21.96 and a beta of 1.13. The firm has a fifty day moving average of $10.30 and a 200-day moving average of $10.70.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The business had revenue of $95.44 million during the quarter, compared to analysts' expectations of $87.55 million. On average, research analysts expect that Dynavax Technologies will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.